Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MANNITOL 15% IN PLASTIC CONTAINER vs MANNITOL 20%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mannitol is an osmotic diuretic that increases plasma osmolality, thereby drawing water from extravascular spaces into the plasma and reducing intracranial pressure. It also increases renal tubular osmotic pressure, inhibiting water reabsorption and promoting diuresis.
Increases plasma osmolality, drawing water from intracellular and interstitial spaces into the extracellular fluid, thereby reducing intracranial pressure and promoting diuresis.
Reduction of elevated intracranial pressure (FDA-approved),Promotion of diuresis in acute renal failure (FDA-approved),Reduction of intraocular pressure (FDA-approved),Irrigant in transurethral prostatic resection (FDA-approved),Enhancement of urinary excretion of toxic substances (off-label)
Reduction of intracranial pressure and cerebral edema,Reduction of intraocular pressure,Promotion of diuresis in acute renal failure (off-label)
Intravenous: 50-100 g (1-2 g/kg) as a 15-25% solution over 30-60 minutes. For cerebral edema: 0.25-1 g/kg IV every 4-6 hours. For oliguric acute kidney injury: test dose of 0.2 g/kg IV over 3-5 minutes; if urine output >50 m L/hr, administer 50-100 g as 15-20% solution over 2-6 hours.
Adult: 50-100 g intravenously as a 20% solution over 30-60 minutes. For cerebral edema: 0.25-1 g/kg IV over 30-60 minutes. For oliguric acute kidney injury: test dose 0.2 g/kg IV over 3-5 minutes.
Terminal elimination half-life approximately 0.5–1 hour in normal renal function; prolonged to 24–36 hours in anuria or severe renal impairment.
Terminal elimination half-life 1.1–1.6 hours in normal renal function; prolonged to 18–36 hours in anuria/end-stage renal disease.
Mannitol is not metabolized; it is excreted unchanged by the kidneys via glomerular filtration, with a small amount reabsorbed in the proximal tubule.
Minimal hepatic metabolism; primarily excreted unchanged by the kidneys.
Renal: >90% excreted unchanged in urine within 24 hours; minimal biliary/fecal elimination (<2%).
Renal, >90% unchanged by glomerular filtration; negligible biliary (<2%) or fecal elimination.
Negligible protein binding (<0.5%); no specific binding proteins identified.
Negligible (<0.1%); does not bind significantly to plasma proteins.
Approximately 0.5–0.7 L/kg (confined to extracellular fluid space; does not cross cell membranes significantly).
0.25–0.4 L/kg; corresponds to extracellular fluid volume; increased in dehydration, decreased in hypervolemia.
Intravenous: 100% (only route used clinically); no oral bioavailability due to poor absorption and osmotic diarrhea.
Intravenous: 100%; oral: <10% (non-absorbed, acts as osmotic laxative).
Contraindicated in anuria. GFR <15 m L/min: avoid use. GFR 15-30 m L/min: use with caution, monitor serum osmolarity and electrolytes. No specific dose adjustment for mild-moderate renal impairment; clinical judgment required.
GFR < 50 m L/min: avoid use due to risk of volume overload and hyperosmolality. GFR 50-80 m L/min: use with caution, monitor serum osmolarity. No specific dose reduction established.
No specific dose adjustment for hepatic impairment; monitor for fluid and electrolyte disturbances.
No adjustment required for Child-Pugh class A or B. Child-Pugh class C: use with caution due to potential fluid and electrolyte imbalances; monitor closely.
Intravenous: 1-2 g/kg as a 15-20% solution over 30-60 minutes. For acute renal failure: test dose of 0.2 g/kg IV over 30 minutes; if urine output >1 m L/kg/hr, continue with 0.5-1 g/kg every 4-6 hours. For cerebral edema: 0.25-1 g/kg IV every 4-6 hours. Maximum infusion rate: 60 g/hour.
For cerebral edema: 0.25-1 g/kg IV as a 20% solution over 30-60 minutes. For elevated intracranial pressure: 0.25-0.5 g/kg IV. Maximum single dose typically 2 g/kg.
Start at lower end of dosing range; monitor renal function, fluid balance, and electrolytes closely due to age-related decreased renal function and higher risk of volume overload.
Elderly patients: lower initial doses (e.g., 25-50 g) recommended due to decreased renal function and higher risk of electrolyte disturbances. Monitor serum osmolarity and renal function closely.
None.
None
Use with caution in patients with heart failure, pulmonary congestion, or renal impairment due to risk of fluid overload and electrolyte disturbances.,Monitor serum electrolytes, osmolality, and renal function during therapy.,Avoid in patients with anuria due to severe renal disease.,Rapid infusion may cause circulatory overload resulting in hyponatremia and hyperosmolality.
May cause volume expansion, electrolyte imbalances, and renal impairment; monitor serum electrolytes, osmolality, and renal function; use with caution in patients with heart failure or pulmonary congestion.
Anuria due to severe renal disease,Severe pulmonary congestion or edema,Active intracranial bleeding (except during craniotomy),Dehydration,Hypersensitivity to mannitol
Anuria due to severe renal disease, severe pulmonary congestion or edema, active intracranial bleeding (except during craniotomy), severe dehydration, and known hypersensitivity.
No specific food interactions. Maintain adequate hydration unless contraindicated. Avoid excessive salt intake as it may counteract diuretic effect.
No known food interactions; however, monitor fluid and electrolyte balance as mannitol induces diuresis.
Mannitol is a pregnancy category C drug. There are no adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. Mannitol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. In the first trimester, risks are unknown; in second and third trimesters, maternal administration may cause fetal electrolyte disturbances due to osmotic diuresis.
Mannitol is not teratogenic in animal studies. In human pregnancy, there are no controlled studies; FDA pregnancy category C. First trimester: theoretical risk due to osmotic shifts, but no documented fetal harm. Second and third trimesters: use only if clearly needed; may cause maternal dehydration and electrolyte disturbances, potentially affecting fetal fluid balance. Avoid in severe maternal renal impairment.
It is not known whether mannitol is excreted in human milk. The M/P ratio is not established. Caution should be exercised when mannitol is administered to a nursing woman. The drug should be used only if clearly needed, considering the potential for adverse effects in nursing infants such as osmotic diuresis and electrolyte imbalance.
Mannitol is excreted into breast milk in trace amounts; M/P ratio not established. Oral bioavailability is low, so infant exposure via breastfeeding is minimal. Compatible with breastfeeding; caution if infant has renal impairment.
Pregnancy may alter pharmacokinetics of mannitol due to increased plasma volume and renal blood flow, potentially increasing clearance. However, specific dose adjustments are not recommended. The usual adult dose (50-200 g per 24 hours) may be used with careful monitoring of maternal hydration status, urine output, and serum osmolality to avoid volume depletion or overload. No standard dose reduction is indicated.
No specific dose adjustments required; pharmacokinetics of mannitol are not significantly altered by pregnancy. Use standard dosing based on indication and renal function. Caution in preeclampsia due to potential for fluid shifts.
Mannitol 15% is an osmotic diuretic used primarily for reduction of intracranial pressure (ICP) and cerebral edema. In emergency settings, administer via IV bolus (0.25-1 g/kg) over 30-60 minutes; onset of ICP reduction occurs within 15-30 minutes. Monitor serum osmolality and avoid if >320 m Osm/L. Use with caution in acute tubular necrosis. Can cause transient volume expansion followed by diuresis; watch for pulmonary edema in heart failure patients. Crystallization may occur at low temperatures; warm and inspect before use.
Monitor serum osmolarity and sodium levels frequently; avoid use in patients with anuria, severe pulmonary congestion, or intracranial hemorrhage. Mannitol may cause acute kidney injury if used in high doses or in patients with pre-existing renal impairment. Administer via in-line filter to prevent crystallization.
This medication is given intravenously to reduce swelling in the brain.,You may experience increased urination, headache, or dry mouth.,Report any chest pain, difficulty breathing, or unusual swelling.,Do not stop or change the infusion rate without medical advice.,Tell your doctor if you have kidney disease, heart failure, or electrolyte imbalances.
This medication is given intravenously to reduce swelling in the brain or to promote urine output.,Report any signs of allergic reaction, chest tightness, or difficulty breathing immediately.,You may experience increased thirst, headache, or nausea during infusion.,Inform your healthcare provider if you have kidney problems, heart failure, or are pregnant.
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MANNITOL 15% IN PLASTIC CONTAINER vs MANNITOL 20%, answered by our medical review team.
MANNITOL 15% IN PLASTIC CONTAINER is a Osmotic Diuretic that works by Mannitol is an osmotic diuretic that increases plasma osmolality, thereby drawing water from extravascular spaces into the plasma and reducing intracranial pressure. It also increases renal tubular osmotic pressure, inhibiting water reabsorption and promoting diuresis.. MANNITOL 20% is a Osmotic Diuretic that works by Increases plasma osmolality, drawing water from intracellular and interstitial spaces into the extracellular fluid, thereby reducing intracranial pressure and promoting diuresis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MANNITOL 15% IN PLASTIC CONTAINER and MANNITOL 20% depend on the specific clinical indication. These are both Osmotic Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MANNITOL 15% IN PLASTIC CONTAINER is: Intravenous: 50-100 g (1-2 g/kg) as a 15-25% solution over 30-60 minutes. For cerebral edema: 0.25-1 g/kg IV every 4-6 hours. For oliguric acute kidney injury: test dose of 0.2 g/kg IV over 3-5 minutes; if urine output >50 m L/hr, administer 50-100 g as 15-20% solution over 2-6 hours.. The standard adult dose of MANNITOL 20% is: Adult: 50-100 g intravenously as a 20% solution over 30-60 minutes. For cerebral edema: 0.25-1 g/kg IV over 30-60 minutes. For oliguric acute kidney injury: test dose 0.2 g/kg IV over 3-5 minutes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining MANNITOL 15% IN PLASTIC CONTAINER and MANNITOL 20%. Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. MANNITOL 15% IN PLASTIC CONTAINER is classified as Category A/B. Mannitol is a pregnancy category C drug. There are no adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. Mannitol should be used during. MANNITOL 20% is classified as Category A/B. Mannitol is not teratogenic in animal studies. In human pregnancy, there are no controlled studies; FDA pregnancy category C. First trimester: theoretical risk due to osmotic shift. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.